DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: NORAMCO, INC.

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before [INSERT 60 DAYS AFTER PUBLICATION IN THE FEDERAL REGISTER].

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION:

The Attorney General has delegated his authority under the Controlled Substances

Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR

0.100(b). Authority to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of manufacturers,
distributors, and dispensers of controlled substances (other than final orders in connection
with suspension, denial, or revocation of registration) has been redelegated to the Deputy

Assistant Administrator of the DEA Office of Diversion Control ("Deputy Assistant
Administrator") pursuant to section 7 of 28 CFR pt. 0, subpt. R, App.

In accordance with 21 CFR 1301.33(a), this is notice that on July 16, 2014, Noramco, Inc., 1440 Olympic Drive, Athens, Georgia 30601, applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled Substance	Schedul
Gamma Hydroxybutyric Acid (2010)	I
Codeine-N-oxide (9053)	I
Dihydromorphine (9145)	I
Morphine-N-oxide (9307)	I
Amphetamine (1100)	II
Methylphenidate (1724)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Hydrocodone (9193)	II
Morphine (9300)	II
Oripavine (9330)	II
Thebaine (9333)	II
Opium tincture (9630)	II
Oxymorphone (9652)	II
Noroxymorphone (9668)	II
Alfentanil (9737)	II
Sufentanil (9740)	II
Carfentanil (9743)	II
Tapentadol (9780)	II
Fentanyl (9801)	II

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Dated: September 26, 2014.

Joseph T. Rannazzisi, Deputy Assistant Administrator.

[FR Doc. 2014-23831 Filed 10/06/2014 at 8:45 am; Publication Date: 10/07/2014]